Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B) has, by information previously announced, conducted a Directed Share Issue. The Directed Share Issue has resulted in a change in the number of shares and votes in the company. Through the Directed Share Issue, the number of shares has increased by 36,811,000 B-shares and the number of votes has increased by 36,811,000.

During December, shareholders exercised 199,756 warrants (TO4B). The number of shares has increased by 199,756 B-shares during the subscription period, and the number of votes has increased by 199,756. The number of warrants remaining for future subscription periods is 1,505,476. The terms of the warrants are published on Episurf Medical’s website.

The total number of shares amounts to 222,040,543, of which 971,024 are A shares, and 221,069,519 are B shares. The total number of votes after the changes amounts to 223,982,591. The share capital has increased by SEK 11,112,625.04 and now amounts to SEK 66,668,546.29.

For more  information, please contact:

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CET on December 30, 2020.